| Autor: |
Nannini, Luis J., Brandan, Nadia, Fernandez, Octavio M. |
| Předmět: |
|
| Zdroj: |
Journal of Asthma; Jun2023, Vol. 60 Issue 6, p1057-1060, 4p |
| Abstrakt: |
Apart from asthma studies that used anti-inflammatory reliever therapy, all trials used SABA as a reliever therapy with higher patient adherence to maintenance therapy than observed in real-world clinical practice. I To the Editor i , The Global Initiative for Asthma (GINA) 2021 strategy report no longer recommends short-acting SB 2 sb -agonists (SABAs) as the preferred reliever therapy without concomitant inhaled corticosteroid (ICS) therapy ([1]). We implemented a multi-pronged strategy, targeting both patients and healthcare providers (Figure 1), which helped achieve our "asthma-zero" goal in >600 patients with asthma in our center, i.e. no recorded asthma hospitalizations and ER visits ([14]). Finally, a systematic review and meta-analysis found that ICS therapy reduces hospital admissions in patients with acute asthma, but there is insufficient evidence that ICS therapy can be used in place of systemic corticosteroid therapy when treating acute asthma ([18]). [Extracted from the article] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
